1.11
+4.72%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biote
From its filings with the US Securities and Exchange Commission
Biote is based in Irving, Texas. Its shares trade on Nasdaq under the ticker BTMD. The SEC classifies its business as medicinal chemicals & botanical products. In the fiscal year to 31 December 2025, it reported revenue of $192.2m and net income of $27.0m. At that date it held total assets of $107.6m and shareholders' equity of −$58.5m.
We operate a high-growth practice-building business within the hormone optimization space. Similar to a franchise model, we provide the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the following components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (“HRT”) products, as well as digital and point-of-care marketing support. We also sell a complementary Biote-branded line of dietary supplements. We generate revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements. By virtue of our historical performance over the past 14 years, we believe that our business model has been successful, remains differentiated, and is well positioned for future growth.
Quoted from its 10-K, filed 13 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 2 Mar 2021
- Employees
- 186
- Website
- haymakeracquisition.com ↗
- Head office
- 1875 W. WALNUT HILL LN #100, IRVING, TX, 75038
- Classification
- Medicinal Chemicals & Botanical Products
- Filer status
- Accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Marc BeerExecutive Chairman of the Board, since 2021$2.7m
- Mr. Bret ChristensenChief Executive Officer, Principal Executive Officer, Director, since 2025
- Mr. Robert PetersonChief Financial Officer, Chief Business Officer$1.8m
- Ms. Mary ConlonVice President - Business Development, General Counsel, Corporate Secretary$1.0m
- Mr. Richard BarreraIndependent Director
- Dr. S. Mark ConeIndependent Director$260,623
- Mr. Andrew HeyerIndependent Director, since 2020$275,099
- Ms. Dana JacobyIndependent Director$272,688
- Ms. Debra MorrisIndependent Director$261,832
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 13
- Environment
- 2
- Social
- 22
- Governance
- 17
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biote Method provides comprehensive practice-building platform for hormone optimization.
- Biote-certified practitioners benefit from education, training, and certification programs.
- Biote-branded dietary supplements complement hormone replacement therapy products.
Weaknesses
- IPO on 2 March 2021 limits historical market data availability.
- 186 employees may restrict scalability for rapid expansion.
- Irving, Texas headquarters location may limit regional market access.
Opportunities
- Growing demand for hormone optimization in Health Care sector.
- Expansion into new regions within the US market.
- Increased adoption of Biote Method by certified practitioners.
Threats
- Competition from established pharmaceutical companies in Hormone Replacement Therapy.
- Regulatory changes affecting hormone therapy practices.
- Potential market saturation in hormone optimization niche.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.